Alar Pharmaceuticals Inc(TW:6785)
NT$80.10+3.60 (+4.71%)
TW:6785
Alar Pharmaceuticals Inc financials statements
NT$80.10
At close:+3.60 (+4.71%)
Alar Pharmaceuticals Inc (6785) Ratios
Alar Pharmaceuticals Inc Ratios
TW:6785's free cash flow for Q2 2026 was NT$-25.73M. For the 2026 fiscal year, TW:6785's free cash flow was decreased by NT$-188.00K and operating cash flow was NT$-25.55M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 31.59 | 44.33 | 12.08 | 92.66 | 118.67 |
| Quick Ratio | 31.59 | 44.33 | 12.08 | 92.66 | 118.67 |
| Cash Ratio | 24.08 | 25.53 | 9.89 | 84.80 | 116.51 |
| Solvency Ratio | -0.89 | 0.34 | 5.07 | -2.06 | -11.00 |
| Operating Cash Flow Ratio | -1.55 | -0.68 | 5.40 | -6.14 | -14.25 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 2.27B | NT$ 2.38B | NT$ 826.93M | NT$ 489.47M | NT$ 523.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.03 | 1.08 | 1.02 | 1.01 |
| Debt Service Coverage Ratio | -922.67 | 1134.07 | 6127.46 | -756.50 | -2897.67 |
| Interest Coverage Ratio | -2071.58 | -2516.44 | 6119.48 | -2114.86 | -4442.62 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.01 | 0.03 | 0.05 | 0.02 |
| Net Debt to EBITDA | 24.18 | -28.39 | -1.87 | 15.44 | 8.51 |
| Profitability Margins | |||||
| Gross Profit Margin | -99.02% | 65.15% | 100.00% | 100.00% | 0.00% |
| EBIT Margin | -2865.60% | 784.22% | 83.36% | -4064.50% | 0.00% |
| EBITDA Margin | -2688.85% | 850.94% | 84.07% | -3663.75% | 0.00% |
| Operating Profit Margin | -6095.10% | -1168.02% | 82.15% | -5815.88% | 0.00% |
| Pretax Profit Margin | -2868.54% | 636.91% | 83.34% | -4067.25% | 0.00% |
| Net Profit Margin | -2894.41% | 312.36% | 81.53% | -2483.88% | 0.00% |
| Continuous Operations Profit Margin | -2894.41% | 312.36% | 81.53% | -2483.88% | 0.00% |
| Net Income Per EBT | 100.90% | 49.04% | 97.83% | 61.07% | 100.00% |
| EBT Per EBIT | 47.06% | -54.53% | 101.45% | 69.93% | 68.85% |
| Return on Assets (ROA) | -3.20% | 0.71% | 39.32% | -3.80% | -11.90% |
| Return on Equity (ROE) | -3.32% | 0.73% | 42.65% | -3.86% | -12.02% |
| Return on Capital Employed (ROCE) | -6.95% | -2.72% | 42.91% | -9.00% | -17.42% |
| Return on Invested Capital (ROIC) | -6.94% | -1.33% | 41.92% | -5.48% | -17.40% |
| Return on Tangible Assets | -3.20% | 1.17% | 39.32% | -3.80% | -11.90% |
| Earnings Yield | -0.39% | 0.19% | 3.19% | -0.30% | -2.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.95 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.16 | 0.43 | 36.76 | 0.08 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.48 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.71 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 383.25 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 383.25 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 383.25 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.73 | -0.57 | 7.08 | -0.58 | -1.11 |
| Free Cash Flow Per Share | -1.77 | -0.59 | 6.97 | -0.60 | -1.14 |
| Dividend Paid and CapEx Coverage Ratio | -5.90 | -0.37 | 63.67 | -28.93 | -40.25 |
| Capital Expenditure Coverage Ratio | -40.28 | -30.55 | 63.67 | -28.93 | -40.25 |
| Operating Cash Flow Coverage Ratio | -32.37 | -62.36 | 286.42 | -12.23 | -66.88 |
| Operating Cash Flow to Sales Ratio | -41.96 | -6.48 | 0.86 | -41.18 | 0.00 |
| Free Cash Flow Yield | -0.58% | -0.42% | 3.31% | -0.52% | -2.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -255.46 | 524.07 | 31.37 | -328.57 | -40.49 |
| Price-to-Sales (P/S) Ratio | 7376.39 | 1610.92 | 25.58 | 8193.75 | 0.00 |
| Price-to-Book (P/B) Ratio | 8.45 | 3.76 | 13.38 | 12.74 | 4.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -171.52 | -240.89 | 30.22 | -192.31 | -40.09 |
| Price-to-Operating Cash Flow Ratio | -175.78 | -248.77 | 29.74 | -198.96 | -41.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.47 | -5.46 | -0.02 | 4.76 | 0.67 |
| Enterprise Value Multiple | -250.15 | 160.92 | 28.55 | -208.20 | -34.34 |
| Enterprise Value | 18.52B | 7.97B | 11.27B | 6.10B | 2.09B |
| EV to EBITDA | -250.15 | 160.92 | 28.55 | -208.20 | -34.34 |
| EV to Sales | 6726.22 | 1369.34 | 24.01 | 7627.92 | 0.00 |
| EV to Free Cash Flow | -156.40 | -204.76 | 28.36 | -179.03 | -32.12 |
| EV to Operating Cash Flow | -160.29 | -211.47 | 27.91 | -185.22 | -32.92 |
| Tangible Book Value Per Share | 35.98 | 37.63 | 15.73 | 9.03 | 9.37 |
| Shareholders’ Equity Per Share | 35.98 | 37.63 | 15.73 | 9.03 | 9.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.51 | 0.02 | 0.39 | 0.00 |
| Revenue Per Share | 0.04 | 0.09 | 8.23 | 0.01 | 0.00 |
| Net Income Per Share | -1.19 | 0.27 | 6.71 | -0.35 | -1.13 |
| Tax Burden | 1.01 | 0.49 | 0.98 | 0.61 | 1.00 |
| Interest Burden | 1.00 | 0.81 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 55.31 | 9.86 | 0.12 | 42.73 | 0.00 |
| SG&A to Revenue | 4.88 | 2.47 | 0.06 | 16.43 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.45 | -1.02 | 1.03 | 1.01 | 0.99 |
Currency in TWD
